Table 1.
Ref. | Study design | Number of patients | Complete CRS | Intraperitoneal chemotherapy | Median follow-up (mo) | Median survival (mo) |
Verwaal et al[12] | Randomized | 105 | NA | HIPEC | 21.6 | 22.3 |
Glehen et al[47] | Retrospective | 506 | 53.5% | HIPEC/EPIC | 53.0 | 19.2 |
Levine et al[46] | Retrospective | 133 | NA | HIPEC | 55.4 | 16.4 |
Elias et al[9] | Retrospective | 48 | NA | HIPEC | 63.0 | 62.7 |
Elias et al[42] | Retrospective | 523 | 84% | HIPEC/EPIC | 45.0 | 30.1 |
CRS: Cytoreductive surgery; NA: Not available; HIPEC: Hyperthermic intraperitoneal chemotherapy; EPIC: Early postoperative intraperitoneal chemotherapy.